Hemophilia is a genetic bleeding disorder afflicting about 20,000 people in the US and over 400,000 people in the world. Severe hemophilia is characterized by frequent joint bleeding, resulting in debilitating arthropathy because of toxic iron depositions (e.g., hemosiderin) in synovium and cartilage. Development of a sensitive, non-invasive biomarker is of high importance to determine efficacy of costly treatment plans. In this study, we investigate the feasibility of ultrashort echo time-based QSM (UTE-QSM) to identify hemosiderin deposition and to provide a sensitive biomarker for joint disease in hemophilia.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords